Annovis Bio raises ~$3.4M in offering of 1.67M shares at $2.05 for Alzheimer's trial

Annovis Bio, Inc.

1,670,732 shares at $2.05 each; gross proceeds ~$3.425M before expenses.
Two board members purchase 1,073,171 shares under separate subscription agreements.
Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease and working capital.
Placement agent H.C. Wainwright receives 7% cash fee and warrants for 83,537 shares at $2.5625.
Closing expected October 28, 2025; lock-up on further issuance until November 28, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.